Hormone replacement therapy for the adolescent patient

Annals of the New York Academy of Sciences

Volumn 1135, Issue , 2008, Pages 204-211

  DiVasta, Amy D ^a   Gordon, Catherine M ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

17 estradiol; Adolescents; Hormone replacement therapy; Hypogonadism

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ESTRONE SULFATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE;

ANOREXIA NERVOSA; BONE; BONE ATROPHY; BREAST DEVELOPMENT; CONFERENCE PAPER; DRUG METABOLISM; GROWTH DISORDER; HEALTH CARE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOGONADOTROPIC HYPOGONADISM; LOW DRUG DOSE; MENSTRUATION; OVARY INSUFFICIENCY; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UTERUS BLEEDING;

EID: 45549084299     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1429.012     Document Type: Conference Paper

References (52)

1. Bondy, C.A. 2007. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J. Clin. Endocrinol. Metab. 92 : 10 25.
2. Altuntas, C.Z., J.M. Johnson & V.K. Tuohy. 2006. Autoimmune targeted disruption of the pituitary-ovarian axis causes premature ovarian failure. J Immunol. 177 : 1988 1996.
3. Bakalov, V.K., J.N. Anasti, K.A. Calis, et al. 2005. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil. Steril. 84 : 958 965.
4. Bihan, H., V. Christozova, J.L. Dumas, et al. 2007. Sarcoidosis: clinical, hormonal, and magnetic resonance imaging (MRI) manifestations of hypothalamic-pituitary disease in 9 patients and review of the literature. Medicine (Baltimore) 86 : 259 268.
5. Welt, C.K., P.C. Smith & A.E. Taylor. 2004. Evidence of early ovarian aging in fragile X premutation carriers. J. Clin. Endocrinol. Metab. 89 : 4569 4574.
6. Cohen, L.E. 2005. Endocrine late effects of cancer treatment. Endocrinol. Metab. Clin. North Am. 34 : 769 789, xi.
7. Forges, T., P. Monnier-Barbarino, B. Leheup & P. Jouvet. 2006. Pathophysiology of impaired ovarian function in galactosaemia. Hum. Reprod. Update 12 : 573 584.
8. Laml, T., O. Preyer, W. Umek, et al. 2002. Genetic disorders in premature ovarian failure. Hum. Reprod. Update 8 : 483 491.
9. Nelson, L.M. & V.K. Bakalov. 2003. Mechanisms of follicular dysfunction in 46,XX spontaneous premature ovarian failure. Endocrinol. Metab. Clin. North Am. 32 : 613 637.
10. Golden, N.H. 2007. Eating disorders in adolescence: what is the role of hormone replacement therapy? Curr. Opin. Obstet. Gynecol. 19 : 434 439.
11. Gordon, C.M. & L.M. Nelson. 2003. Amenorrhea and bone health in adolescents and young women. Curr. Opin. Obstet. Gynecol. 15 : 377 384.
12. Beshay, V.E., J.E. Beshay & L.M. Halvorson. 2007. Pituitary tumors: diagnosis, management, and implications for reproduction. Semin. Reprod. Med. 25 : 388 401.
13. DiVasta, A.D., M.R. Laufer & C.M. Gordon. 2007. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J. Pediatr. Adolesc. Gynecol.
14. ACOG Committee Opinion. Number 310, April 2005. Endometriosis in adolescents. Obstet. Gynecol. 105 : 921 927.
15. Emans, S.J., M.R. Laufer & D.P. Goldstein. 2005. Pediatric & Adolescent Gynecology, 5th ed. Lippincott Williams & Wilkins. Philadelphia, PA.
16. Giedd, J.N., L.S. Clasen, R. Lenroot, et al. 2006. Puberty-related influences on brain development. Mol. Cell. Endocrinol. 254-255 : 154 162.
17. Genazzani, A.R., N. Pluchino, S. Luisi & M. Luisi. 2007. Estrogen, cognition and female ageing. Hum. Reprod. Update 13 : 175 187.
18. Spiliotis, B.E. 2006. Growth and long-term hormonal therapy. Pediatr. Endocrinol. Rev. 3 (Suppl. 1 192 194.
19. Koh, K.K., D.K. Jin, S.H. Yang, et al. 2001. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103 : 1961 1966.
20. Bairey Merz, C.N., B.D. Johnson, B.L. Sharaf, et al. 2003. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J. Am. Coll. Cardiol. 41 : 413 419.
21. http://www.vivelledot.com/Files/PDF/PrescribingInformation.pdf.
22. http://www.pharma.us.novartis.com/product/pi/pdf/estraderm.pdf.
23. Peter, F. 2003. Sex steroid replacement during and after the induction of puberty. Growth Horm. IGF Res. 13 (Suppl. A S136 142.
24. Marty, J.P. 1996. New trends in transdermal technologies: development of the skin patch, Menorest. Int. J. Gynaecol. Obstet. 52 (Suppl. 1 S17 20.
25. Ankarberg-Lindgren, C., M. Elfving, K.A. Wikland & E. Norjavaara. 2001. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J. Clin. Endocrinol. Metab. 86 : 3039 3044.
26. MacGillivray, M.H. 2004. Induction of puberty in hypogonadal children. J. Pediatr. Endocrinol. Metab. 17 (Suppl. 4 1277 1287.
27. http://www.prometrium.com/pdf/HCP Full Prescribing Info/Prometrium Full Prescribing Info.pdf.
28. Van Den Heuvel, M.W., A.J. van Bragt, A.K. Alnabawy & M.C. Kaptein. 2005. Comparison of ethinyl estradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72 : 168 174.
29. Kalantaridou, S.N., K.K. Naka, E. Papanikolaou, et al. 2004. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J. Clin. Endocrinol. Metab. 89 : 3907 3913.
30. Lieberman, S. 1996. Are the differences between estradiol and other estrogens, naturally occurring or synthetic, merely semantical? J. Clin. Endocrinol. Metab. 81 : 850 851.
31. http://www.enjuvia.com/hcp/prescribing_information/Default.aspx.
32. Rosenfield, R.L., N. Perovic, N. Devine, et al. 1998. Optimizing estrogen replacement treatment in Turner syndrome. Pediatrics 102 (2 Pt 3 486 488.
33. Lissett, C.A. & S.M. Shalet. 2003. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J. Clin. Endocrinol. Metab. 88 : 4668 4672.
34. Mah, P.M., J. Webster, P. Jonsson, et al. 2005. Estrogen replacement in women of fertile years with hypopituitarism. J. Clin. Endocrinol. Metab. 90 : 5964 5969.
35. O'Sullivan, A.J., L.J. Crampton, J. Freund & K.K. Ho. 1998. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102 : 1035 1040.
36. Zegura, B., I. Keber, M. Sebestjen & W. Koenig. 2003. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 168 : 123 129.
37. Paterson, W.F., A.S. Hollman & M.D. Donaldson. 2002. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clin. Endocrinol. (Oxf). 56 : 359 365.
38. Illig, R., C. DeCampo, M.R. Lang-Muritano, et al. 1990. A physiological mode of puberty induction in hypogonadal girls by low dose transdermal 17 beta-oestradiol. Eur. J. Pediatr. 150 : 86 91.
39. Kiess, W., G. Conway, M. Ritzen, et al. 2002. Induction of puberty in the hypogonadal girl-practices and attitudes of pediatric endocrinologists in Europe. Horm Res. 57 : 66 71.
40. Drobac, S., K. Rubin, A.D. Rogol & R.L. Rosenfield. 2006. A workshop on pubertal hormone replacement options in the United States. J. Pediatr. Endocrinol. Metab. 19 : 55 64.
41. Cromer, B.A., M. Stager, A. Bonny, et al. 2004. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J. Adolesc. Health 35 : 434 441.
42. Polatti, F., F. Perotti, N. Filippa, et al. 1995. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception 51 : 221 224.
43. Rome, E., J. Ziegler, M. Secic, et al. 2004. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J. Pediatr. Adolesc. Gynecol. 17 : 373 377.
44. Bachrach, L.K., D. Guido, D. Katzman, et al. 1990. Decreased bone density in adolescent girls with anorexia nervosa. Pediatrics 86 : 440 447.
45. Grinspoon, S., E. Thomas, S. Pitts, et al. 2000. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann. Intern. Med. 133 : 790 794.
46. Golden, N.H. 2003. Osteopenia and osteoporosis in anorexia nervosa. Adolesc. Med. 14 : 97 108.
47. Golden, N.H., L. Lanzkowsky, J. Schebendach, et al. 2002. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J. Pediatr. Adolesc. Gynecol. 15 : 135 143.
48. Gordon, C.M., E. Grace, S.J. Emans, et al. 2002. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J. Clin. Endocrinol. Metab. 87 : 4935 4941.
49. Klibanski, A., B.M. Biller, D.A. Schoenfeld, et al. 1995. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J. Clin. Endocrinol. Metab. 80 : 898 904.
50. Grinspoon, S., L. Thomas, K. Miller, et al. 2002. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. 87 : 2883 2891.
51. Liu, S.L. & C.M. Lebrun. 2006. Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review. Br. J. Sports Med. 40 : 11 24.
52. Robinson, E., L.K. Bachrach & D.K. Katzman. 2000. Use of hormone replacement therapy to reduce the risk of osteopenia in adolescent girls with anorexia nervosa. J. Adolesc. Health 26 : 343 348.